DPP4 in Diabetes.

Röhrborn D, Wronkowitz N, Eckel J. · 2015

Read DPP4 in Diabetes. by Röhrborn D, Wronkowitz N, Eckel J. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4515598.txt.

Introduction

Diana Röhrborn, Nina Wronkowitz, and Juergen Eckel review the enzyme DPP4 and its role in diabetes, in Frontiers in Immunology in 2015. DPP4 sits on many cell surfaces and snips the ends off small protein signals. Among its targets are incretins, gut hormones that prompt insulin release after meals.

Blocking DPP4 with gliptin drugs keeps incretins active longer, which is why the family is used in type 2 diabetes. The review sums up that drug story, then turns to a second life of the enzyme: DPP4 can be cut loose from the cell surface and float in blood. There it acts like a fat-tissue hormone, and levels run high in obesity and diabetes. A newfound receptor for the loose form hints at links to heart and vessel disease.

Catalog record

CREATORRöhrborn D, Wronkowitz N, Eckel J.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE127 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4515598

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

DPP4 in Diabetes By Diana Röhrborn, Nina Wronkowitz, Juergen Eckel Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2015.00386 ABSTRACT Abstract Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors, neuropeptides, and the incretin hormones. Expression of DPP4 is substantially dysregulated in a variety of disease states including inflammation, cancer, obesity, and diabetes. Since the incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP), are major regulators of post-prandial insulin secretion, inhibition of DPP4 by the gliptin family of drugs has gained considerable interest for the therapy of type 2 diabetic patients. In this review, we summarize the current knowledge on the DPP4–incretin axis and evaluate most recent findings on DPP4 inhibitors. Furthermore, DPP4 as a type II transmembrane protein is also known to be cleaved from the cell membrane involving different metalloproteases in a cell-type-specific manner. Circulating, soluble DPP4 has been identified as a new adipokine, which exerts both para- and endocrine effects. Recently, a novel receptor for soluble DPP4 has been identified, and data are accumulating that the adipokine-related effects of DPP4 may play an important role in the pathogenesis of cardiovascular disease. Importantly, circulating DPP4 is augmented in obese and type 2 diabetic subjects, and it may represent a molecular link between obesity and vascular dysfunction. A critical evaluation of the impact of circulating DPP4 is presented, and the potential role of DPP4 inhibition at this level is also discussed. Keywords: CD26/DPP4, soluble DPP4, type 2 diabetes mellitus, incretins, DPP4 inhibitors/gliptins, multifunctional enzyme INTRODUCTION Dipeptidyl-peptidase (DPP) 4, which is also known as CD26, is a ubiquitously expressed glycoprotein of 110 kDa, which was first characterized by Hopsu-Havu and Glenner (1). DPP4 is a type II transmembrane protein, which is also cleaved off the membrane and released into the circulation by a process called shedding (2, 3). The importance of DPP4 for the scientific and medical community raised substantially since the approval of DPP4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). These so-called gliptins increase the incretin levels and therefore prolong the post-prandial insulin action. Since soluble DPP4 is characterized as an adipokine (4) and also correlates with parameters of the metabolic syndrome (5), it might also be an important molecular biomarker. DPP4 is a multifunctional enzyme, which serves as a binding partner for numerous peptides, among which are adenosine deaminase (ADA) and extracellular matrix proteins (2, 6, 7). Moreover, as a serine protease, DPP4 cleaves numerous substrates, which further amplifies its complexity of action. Thus, DPP4 is involved in signaling processes, immune cell activation, and its dysregulated expression and release is associated with numerous diseases. In the present review, we wanted to emphasize the complex function of DPP4 with special focus on its association to T2DM. Furthermore, we wanted to offer a different perspective of the current view of DPP4 beyond the inhibition of its protease activity (8–10). The first part of the present review is dealing with general information about DPP4 and its numerous biological functions in regard to T2DM and its treatment. The last section collects the current knowledge about how DPP4 with its pleiotropic functions, as described before, affects several organs, thereby playing a pivotal role in the development of T2DM and its comorbidities. GENERAL INFORMATION ON DPP4 Biology of DPP4 The following part will deal with the domain architecture and respective relevance of these domains for the functionality of DPP4. Dipeptidyl-peptidase 4 (EC3.4.14.5) is a type II transmembrane protein, which groups together with fibroblast-activation protein α (FAP), the resident cytoplasmic proteins, DPP8 and DPP9, and the non-enzymatic members, DPP6 and DPP10, to the serine peptidase subfamily S9B. All of these proteins share a typical α/β hydrolase fold (2, 6). The DPP4 protein consists mainly of 4 domains: a short cytoplasmic domain (1–6), a transmembrane domain (TMD) (7–28), a flexible stalk segment (29–39), and the extracellular domain (40–766), which can be further separated by a highly glycosylated region, the cysteine-rich region, and the catalytic region (Figure 1). [Figure: Domain structure of DPP4 [adapted from Ref. (2)]. Schematic representation of the membrane-bound DPP4 monomer. The extent of the circulating and soluble form of DPP4 is illustrated on the left in blue. The shedding of DPP4 from the membrane by indicated matrix metalloproteinases is shown by a scissor symbol in red. The vertical black bar on the right represents the primary structure with the delineation of the different regions. In green are interactions collected, which occur in the indicated region of the DPP4 structure. MMP, matrix metalloproteinase; M6P/IGFII, mannose-6 phosphate/insulin-like growth factor 2.] As a member of the type II transmembrane proteins, DPP4 contains a typical signal peptide, which is necessary for the targeting to the endoplasmatic reticulum and the initiation of the translocation across the cell membrane. In contrast to the classically secreted proteins, the signal peptide is not cleaved off, but serves as a membrane anchor. We were able to show that the circulating form of DPP4 (sDPP4), which lacks the cytoplasmic domain and the transmembrane region, is cleaved off the membrane of human adipocytes and smooth muscle cells in a process called shedding by the involvement of matrix metalloproteases (MMPs) (3). Within the TMD, it could be shown that proline residues play an important role for the translocation of membrane-anchored proteins, such as DPP4. Chung and colleagues (11) studied single proline substitution throughout the TMD of DPP4. They were able to show that translocation and integration into the membrane are determined by the hydrophobicity, conformation, and also the location of proline within the TMD. Furthermore, the position of proline relative to other prolines and the location of highly hydrophobic residues within the TMD are important for correct translocation and membrane integration of DPP4. In addition to the TMD, the glycosylation of DPP4 is also important for the correct trafficking of DPP4. Carbohydrates account for approximately 20% of the total molecular mass of DPP4 and cause heterogeneity of this protein depending on the location on different cell types. Two highly conserved glutamate residues (205 and 206) within the glycosylated region are essential for the activity of DPP4 (12). Interestingly, six of the nine N-glycosylation sites are located within the glycosylated region. These glycosylation sites are mostly conserved among species. They are necessary for folding, stability, and intracellular trafficking (13). Other modifications like sialylation and/or O-glycosylation have an impact on targeting DPP4 to the cell membrane. Sialyation of DPP4 increases significantly with age, and hypersialyation occurs in patients with HIV infection (14). Not only glycosylation and residues within the TMD are important for the cellular function of DPP4 but also dimerization. DPP4 can be found as monomer, homodimer, or even as homotetramer on the cell surface of cells. DPP4 needs dimerization for enzymatic activity, and this is the predominant form of DPP4 (15). Dimerization occurs upon interaction with DPP4 itself or with other binding partners, e.g., FAP (16, 17), and occurs via interaction with the cysteine-rich region. Through its interaction with several proteins, DPP4 can act also in an enzymatic activity-independent way. Through this interaction, DPP4 is linked to various mechanisms like immune response and tumor invasion.

Read the complete text